Shattuck Labs (STTK) Projected to Post Earnings on Wednesday

Shattuck Labs (NASDAQ:STTK - Get Free Report) will likely be posting its quarterly earnings results on Wednesday, February 26th. Analysts expect Shattuck Labs to post earnings of ($0.32) per share and revenue of $1.00 million for the quarter.

Shattuck Labs Trading Up 6.2 %

STTK stock traded up $0.08 during midday trading on Friday, hitting $1.37. 179,841 shares of the company's stock were exchanged, compared to its average volume of 122,953. Shattuck Labs has a 1-year low of $0.94 and a 1-year high of $11.76. The stock has a market capitalization of $65.40 million, a PE ratio of -0.90 and a beta of 1.70. The business has a 50-day simple moving average of $1.19 and a two-hundred day simple moving average of $1.85.

Insider Activity at Shattuck Labs

In other news, Director Redmile Group, Llc acquired 133,371 shares of Shattuck Labs stock in a transaction dated Wednesday, December 4th. The shares were acquired at an average cost of $1.25 per share, for a total transaction of $166,713.75. Following the acquisition, the director now owns 5,539,724 shares of the company's stock, valued at $6,924,655. This trade represents a 2.47 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 10.50% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

STTK has been the topic of a number of research analyst reports. Needham & Company LLC reissued a "hold" rating on shares of Shattuck Labs in a research report on Thursday, November 14th. HC Wainwright reaffirmed a "neutral" rating on shares of Shattuck Labs in a research note on Friday, November 15th. Four investment analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Shattuck Labs presently has an average rating of "Hold" and a consensus price target of $8.67.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.